2024-10-22 - Analysis Report
## Regeneron Pharmaceuticals Inc. (REGN) Stock Analysis Report

**Company Overview:** Regeneron Pharmaceuticals Inc. is a biotechnology company that develops and commercializes life-saving medicines for serious diseases. 

**1. Performance Comparison:**

* **Cumulative Return:**  REGN has a cumulative return of 88.97%, compared to 137.88% for the S&P 500 (VOO).
* **Relative Performance:**  REGN currently lags behind the S&P 500 by -48.91%. This signifies that the stock is performing relatively lower compared to the benchmark index, placing it in the 28.36th percentile of its historical performance range.

**2. Recent Price Movement:**

* **Closing Price:** $990.68
* **5-day Moving Average:** $1005.53
* **20-day Moving Average:** $1023.85
* **60-day Moving Average:** $1103.98
* **Analysis:**  The stock is currently trading below its 5, 20, and 60-day moving averages, suggesting a potential downtrend.

**3. Technical Indicators:**

* **RSI:** 26.43 - This indicates that the stock is currently in oversold territory, potentially signaling a rebound.
* **PPO:** 0.04 -  A positive PPO value suggests a potential bullish trend, but it is very close to zero, which could indicate a weak trend.
* **Delta_Previous_Relative_Divergence:** -27.24 - This negative value suggests a short-term downtrend, indicating that the stock is currently underperforming compared to its recent historical trends.
* **Expected Return:** 0.0% -  This indicates that over the long term (2+ years), with regular investments, you can expect a return similar to the S&P 500.

**4. Recent Earnings and Outlook:**

| Date       | EPS   | Revenue     |
|------------|-------|-------------|
| 2024-08-01 | 13.25 | 3.55 B$     |
| 2024-05-02 | 6.7   | 3.15 B$     |
| 2023-11-02 | 9.48  | 3.36 B$     |
| 2023-08-03 | 9.05  | 3.16 B$     |
| 2024-08-01 | 9.05  | 3.16 B$     |

**Analysis:** Regeneron's latest earnings report for Q2 2024 showed a significant increase in EPS and revenue compared to previous quarters, exceeding analyst expectations. This positive earnings trend suggests the company is performing well and may continue to grow in the coming quarters.

**5. News and Recent Issues:**

**Recent Market Outlook:** Regeneron has been facing some recent market headwinds. The stock price has declined significantly in recent months, primarily due to concerns about the company's growth prospects. Analyst opinions are mixed, with some expecting a rebound while others remain cautious.  

**Analyst Opinions:** 
* **Performance Highlights:** Despite recent challenges, Regeneron remains a company with strong fundamentals and a promising pipeline of innovative medicines. Investors should closely monitor the company's progress in clinical trials and new product launches for future growth potential. 

**6. Comprehensive Analysis:**

Regeneron Pharmaceuticals Inc. (REGN) is currently in a period of relative weakness compared to the broader market. Despite a strong recent earnings performance, the stock has experienced a decline in price.  Technical indicators suggest a possible rebound, with the stock being in oversold territory. However, the short-term downtrend suggests caution. Long-term investors might consider REGN as a potential growth opportunity, but it's crucial to monitor the company's progress in clinical trials and the overall market sentiment. 

**7. Recommendations:**

* Monitor key developments in the company's clinical trials and new product launches. 
* Pay attention to changes in analyst ratings and market sentiment.
* Consider a long-term investment strategy with regular investments to potentially benefit from the company's growth potential. 

**Disclaimer:** This analysis is for informational purposes only and should not be considered as financial advice. Always conduct thorough research and consult with a qualified financial advisor before making any investment decisions. 
